Loading, please wait ...

News Analytics

WASHINGTON -- The FDA has approved pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease, the agency announced Friday. Hallucinations or delusions can occur in as many as 50% of patients with Parkinson's disease at some time during the course of their illness, the FDA said in a press release.

The Angle

Subject Matter

  • Science and technology 40.70%
  • Healthcare 38.37%
    • Hospitals, doctors and medical care 100.00%
  • Business, economics, society 20.93%
    • Society and people 100.00%

Emotional Reaction






Dimensions/Depth Chart

If you find a dimension intereseting, we recommend you pick up one or two facts that you find intriguing and place them into your memory. That way you will have 2nd degree information about the topic if it comes up in conversation.

Accordingly, you can do the same with others as well.